Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Peter Marks
Biotech
How Peter Marks plans to prevent '3 billion visits' to FDA
Accelerated approval—controversial, yes—but absolutely necessary for small, pre-revenue biotechs, the FDA’s Peter Marks, M.D., Ph.D., said Wednesday.
Annalee Armstrong
May 8, 2024 11:05am
Peter Marks says FDA ready to review novel cancer vaccines
Apr 3, 2024 2:39pm
Biogen's top dealmaker is keen on rare disease meds
Mar 5, 2024 10:20am
FDA's Peter Marks doesn't plan to retire soon—Chutes & Ladders
Aug 4, 2023 9:30am
Peter Marks: Gene editing has met regulatory reality
Jul 31, 2023 3:14pm
FDA's Marks wants more quick approvals for rare disease drugs
Jul 28, 2023 11:36am